key: cord-0718035-tbwcwagv
authors: Yao, Changfu; Bora, Stephanie A.; Parimon, Tanyalak; Zaman, Tanzira; Friedman, Oren A.; Palatinus, Joseph A.; Surapaneni, Nirmala S.; Matusov, Yuri P.; Chiang, Giuliana Cerro; Kassar, Alexander G.; Patel, Nayan; Green, Chelsi ER.; Aziz, Adam W.; Suri, Harshpreet; Suda, Jo; Lopez, Andres A.; Martins, Gislâine A.; Stripp, Barry R.; Gharib, Sina A.; Goodridge, Helen S.; Chen, Peter
title: Cell type-specific immune dysregulation in severely ill COVID-19 patients
date: 2020-12-16
journal: Cell Rep
DOI: 10.1016/j.celrep.2020.108590
sha: 7a599bdf39d90e66876d85466156e202a2d9e850
doc_id: 718035
cord_uid: tbwcwagv

Recent studies have demonstrated immunologic dysfunction in severely ill COVID-19 patients. We use single-cell RNA sequencing (scRNA-seq) to analyze the transcriptome of peripheral blood mononuclear cells (PBMC) from healthy (n=3) and COVID-19 patients with moderate disease (n = 5), acute respiratory distress syndrome (ARDS, n = 6), or recovering from ARDS (n = 6). Our data reveal transcriptomic profiles indicative of defective antigen presentation and interferon responsiveness in monocytes from ARDS patients, which contrasts with higher responsiveness to interferon signaling in lymphocytes. Furthermore, genes involved in cytotoxic activity are suppressed in both NK and CD8 lymphocytes, and B cell activation is deficient, which is consistent with delayed viral clearance in severely ill COVID-19 patients. Our study demonstrates that COVID-19 patients with ARDS have a state of immune imbalance in which dysregulation of both the innate and adaptive immune responses may be contributing to a more severe disease course.

SARS-CoV-2 infection has quickly spread worldwide to cause the COVID-19 pandemic . Coronaviruses are single, positive-stranded RNA viruses that can infect a range of hosts. Some are known to cause seasonal, upper respiratory infections (i.e. common colds), but coronaviruses that cause severe lower respiratory infection have emerged, including those that cause severe acute respiratory syndrome (SARS), Middle Eastern respiratory syndrome (MERS), and now COVID-19 (Cui et al., 2019; Drosten et al., 2003; Zaki et al., 2012) .

SARS-CoV-2 has reached pandemic proportions and is likely to remain a world health emergency until an effective vaccine is widely available due to limited treatments and a high likelihood of recurrent outbreaks. The World Health Organization lists the primary symptoms of COVID-19 as fever, dry cough, and fatigue but also include other symptoms such as diarrhea, loss of taste and smell, and rashes. Those over 60 years of age and people with obesity, cardiovascular disease, and diabetes have the highest risk for severe COVID-19 (Ebinger et al., 2020; Grasselli et al., 2020) . Most COVID-19 patients have mild respiratory illness, however, about 20% become seriously ill and require hospitalization due to pneumonia (Wu and McGoogan, 2020) . This can progress into acute respiratory distress syndrome (ARDS) and systemic inflammation referred to as "cytokine storm" (Ye et al., 2020) .

Instead of beneficial antiviral immunity in response to infection, severe COVID-19 is characterized by dysregulated immune responses that allows the virus to persist, causing lung damage, ARDS, and systemic inflammation (Giamarellos-Bourboulis et al., 2020) . While mechanisms underlying SARS-CoV-2 evasion of antiviral immunity and pathogenic inflammation are not clear at this time, commonalities in the pathogenic response with this novel coronavirus and SARS-CoV-1 and MERS-CoV have become apparent (Felsenstein et al., 2020; Ye et al., 2020) . Cells sense RNA viruses using endosomal and cytosolic pattern recognition receptors (PRRs) which signal through other mediators including TNF receptor-associated factors (TRAF) 3 and 6 to activate interferon regulatory factors (IRF) and NFκΒ, resulting in J o u r n a l P r e -p r o o f 5 transcription of early antiviral type I interferons by resident alveolar macrophages (AMs) and epithelial cells in the lungs, which sets up an immune response that clears the virus and resolves inflammation (Lester and Li, 2014) . SARS-CoV-1, and likely SARS-CoV-2, inhibit multiple viral sensing PRRs and downstream signals, effectively blocking recognition of virus and early antiviral type I interferon, and initiating a dysregulated inflammatory cascade that can lead to ARDS and systemic inflammation (Hu et al., 2017; Li et al., 2016; Siu et al., 2009) .

Moreover, transcriptomic analysis of PBMC from COVID-19 patients found upregulated proinflammatory pathways in monocytes and CD4 T cells, suggesting that the basic hallmarks of the "cytokine storm" in COVID-19 parallel SARS and MERS (Wen et al., 2020) . However, we are now also appreciating immunologic dysfunctions that may be causing a more severe disease course (Hadjadj et al., 2020; Lee et al., 2020; Wilk et al., 2020) .

COVID-19 patients have higher circulating levels of IL-6, TNF-α, and CXCL10, particularly those with severe disease, and these "early" cytokines are sustained weeks into infection suggesting an inability to resolve inflammation (Xiong et al., 2020; .

Adaptive immune cells recruited from nearby lymph nodes (via circulatory and lymphatic systems) can also contribute to pathogenic inflammation in the lung, particularly if polarized to Th1 and Th17 responses that contribute to neutrophil recruitment and pro-inflammatory monocyte/macrophage activation (Wong et al., 2019) . However, severe lung damage due to pneumonia or sepsis is more often characterized by a lack of adaptive immune cells in the periphery (Bermejo-Martin et al., 2017; Roth et al., 2003) . This is due to migration of cells to sites of inflammation, but also T cell dysfunction and death (Hotchkiss et al., 2005; Nakajima et al., 2010; Roth et al., 2003) . Prolonged antigen stimulation and pro-inflammatory cytokine exposure cause T cell exhaustion and apoptosis, leading to insufficient B cell activation and loss 6 Characterization of T cells from COVID-19 patients found increased surface expression of exhaustion markers Tim-3 and PD-1, decreased expression of pathways involved in T cell expansion, and increased expression of apoptotic pathways (Diao et al., 2020; Wen et al., 2020; Xiong et al., 2020) . Therefore, dysfunction of circulating T and B cells during ARDS may result in an inability to resolve inflammation and perpetuate the systemic inflammation caused by the cytokine storm.

The innate-driven pathogenic inflammation and suppressed adaptive immunity during ARDS in COVID-19 patients indicate dysfunction in immune regulation and the switch from innate to adaptive immunity. To better understand this dysregulated immune response that drives patients to have more severe illness from SARS-CoV-2 infection, we used single-cell RNA sequencing (scRNA-seq) to analyze the transcriptome of PBMCs collected from hospitalized COVID-19 patients with a moderate course of disease (moderate group) and those that developed ARDS (severe group). Samples were collected within the first 5 days of hospitalization to minimize the potential for therapeutic interventions to confound interpretation of the data. As expected, when we compared the samples from acutely ill COVID-19 patients (moderate and severe groups) to healthy controls, we found enrichment of viral-induced immunologic pathways. We next focused our analysis on the COVID-19 patient groups and investigated the signals that drive lung inflammation in ARDS. We also delineated novel pathways activated during the resolution of lung inflammation by comparing the severe group to those recovering from ARDS (recovering group). Severely ill patients had an overall higher activation of inflammatory pathways in comparison to moderate and recovering patients.

However, we unexpectedly found that patients with severe SARS-CoV-2 infection had monocytes with transcriptomic profiles consistent with a blunted interferon response and dysregulation of antigen presentation as well as defective humoral and lymphocyte cytotoxic activity that could be contributing to the delayed viral clearance found in severely ill patients. The implications of these results are clinically relevant and indicate that treatment of 8

We identified and collected blood for buffy coat samples from hospitalized patients confirmed to have SARS-CoV-2 infection (Supplemental Table 1 ). There were no significant differences in age, white blood cell count, cell subsets, and hematocrit between the three groups (acutely ill patients with moderate or severe disease, and patients recovering from ARDS), but the platelet count was decreased in the severe versus moderate group (Fig. 1A &   1B ). Using available clinical data, we compared the levels of various inflammatory markers in the blood between groups at the time of sample collection and identified a significantly higher level of C-reactive protein in severe patients reflecting the hyperinflammatory state relative to moderate patients (Fig. 1C ).

Using scRNA-seq, we first compared the transcriptome of PBMCs from healthy controls Table 2 ) and performed gene ontology analysis of the significantly upand downregulated differentially expressed genes between acutely ill COVID-19 patients (moderate and severe groups) and healthy controls (Supplemental Fig. 2 and Supplemental Table 3 ). Consistent with their paucity among circulating immune cells, insufficient conventional and plasmacytoid dendritic cells (cDCs and pDCs) were captured for analysis. Neutrophils were not identified because they, unlike other peripheral blood subsets, do not tolerate the cell freezing process (Wilk et al., 2020) .

J o u r n a l P r e -p r o o f 9 As expected, the response to type I interferon was activated in peripheral immune cells from COVID-19 patients compared to healthy controls (Fig. 1F Table 3 ).

To understand why some patients have a less severe disease course whereas others develop ARDS, we next analyzed immune cell populations within the scRNA-seq data from moderate, severe, and recovering COVID-19 patients (Supplemental Fig. 1C -D). NK cells are an important arm of the innate lymphocytic antiviral response (Abel et al., 2018) . We compared the moderate versus severe group to identify differences in NK cell gene expression that may determine why some have a more benign course of disease compared to those that develop ARDS (Fig. 2, Supplemental Fig. 3A -C and Supplemental Table 4 ). Pathway analysis revealed differences in the NK cell transcriptome between groups. Biological processes that were highly represented by genes upregulated and downregulated in severe patients compared to moderate patients were identified ( Fig. 2A and Supplemental Table 4 ). Patients with severe disease have higher respiratory viral loads (Zheng et al., 2020) . Accordingly, biological processes such as "response to type I interferon", "response to virus", "response to interferon-gamma", and "response to interferon-beta", among several others characteristic of a higher viral response were significantly upregulated in the severe group compared to moderate.

Comparing critically ill patients with ARDS during their acute illness (i.e., severe group) to those that are recovering from severe disease could provide insight into pathways that drive the non-resolving inflammation in ARDS pathogenesis (Matthay et al., 2012) . Thus, we compared the biological processes that were affected by both up-and downregulated genes between severe and recovering groups ( Fig. 2B and Supplemental Table 4 ). The recovering group had a resolution of the antiviral pathways, which would be expected from the waning J o u r n a l P r e -p r o o f 10 respiratory viral load over time. The transcriptomic response to both type I and II interferons was clearly upregulated in NK cells from the severe group in comparison to the moderate and recovering groups ( Fig. 2C and Supplemental Fig. 3A ). Despite this response, which reflects a higher respiratory viral load in the severe group, expression of genes associated with cytotoxic function was lower than in the moderate and recovering groups, suggesting a dysfunctional effector antiviral response by NK cells in ARDS patients ( Table 5 )to investigate the biological processes that differentiate the severity of disease and those that are activated during the recovery phase. CD8 T cells had appropriate activation of interferon signaling that correlated with the disease severity ( Fig. 3A-C and Supplemental Fig. 3D ). We also found a gene signature indicating increased apoptosis in CD8 T cells from the severe group, which is consistent with prior reports (Merad and Martin, 2020) and could be driving the lymphopenia associated with COVID-19 illness ( Table 6 ). Consistent with NK and CD8 T lymphocytes, the severe group had a transcriptome that was consistent with a higher interferon response in CD4 T cells when compared to moderate patients, and this was appropriately Taken together, these transcriptomic findings indicate that NK and T lymphocytes in severely ill COVID-19 patients, who have higher respiratory viral titers and delayed clearance of SARS-CoV-2 (Merad and Martin, 2020) , have an expected stronger response to interferon signaling. Moreover, T lymphocytes have a gene signature consistent with increased activation of metabolic and apoptotic pathways. However, both innate and adaptive cytotoxic lymphocytes have dysfunctional cytotoxic activity-associated pathways in severely ill COVID-19 patients

B lymphocytes also play an important role in the antiviral response (Chiu and Openshaw, 2015) . We evaluated B cells and plasma cells to determine the differentially expressed genes between patient groups ( Table 7 ). Similar to NK and T lymphocytes, the B lymphocytes also had changes in their gene signature that was consistent with higher interferon-mediated responses and activation of apoptotic signals in severe patients compared to both the moderate and recovering groups ( In order to understand the pathways that are activated in B cells during the resolution from SARS-CoV-2 infection, we used Ingenuity Pathway Analysis (IPA) to evaluate canonical pathways enriched among the 642 genes that were upregulated in the recovering group 12 compared to the severe group. The top canonical pathways enriched among these genes were B cell receptor signaling (FDR: 2.5 x 10 -11 ), IL3 signaling (FDR: 4.0 x 10 -6 ) and PI3K signaling (FDR: 3.9 x10 -7 ), which are important signals required for B cell memory and the humoral response (Supplemental Table 7 ). We performed causal network analysis to understand the upstream signals that regulate the differential upregulation of genes in the recovering patients relative to the severe group and identified SYK, which is a critical controller of B cell differentiation, maturation, and signal transduction by the B cell receptor, as the top upstream regulator candidate among the differentially expressed genes ( Fig. 5F ) (Mocsai et al., 2010) .

Emerging evidence demonstrates disruptions to the myeloid compartment in COVID-19 patients (Wilk et al., 2020) . As expected, classical monocytes comprised the majority of the cells 

To further evaluate the potential mechanisms that were driving the selective immunodeficiencies identified within various cell compartments, we performed a canonical pathway analysis with IPA. In contrast to standard GO analysis where activation or inhibition of a process is inferred from up-and downregulation of its member genes respectively, canonical pathway analysis incorporates prior knowledge of the overall consequences of up-and downregulation of individual members of a process in activating or suppressing that pathway (e.g., downregulation of an inhibitor can lead to the activation of a process). In this analysis, we found cell-specific enrichment patterns, for example, CD4 and CD8 T cells had significant activation of the T cell exhaustion pathway in the severe versus moderate group (Supplemental Table 9 ), which is consistent with other reports (Wilk et al., 2020) .

We next explored patterns of altered signaling pathway changes across all cell compartments (Fig. 7A ). Oxidative phosphorylation pathways were uniformly elevated in the severe group when compared to the moderate and recovering groups, likely reflecting the increased metabolic state with more severe infection. In contrast, signaling by sirtuins, which are known mediators of antiviral defenses (Budayeva et al., 2016; Koyuncu et al., 2014) , was suppressed in severe conditions across all cell compartments. As with our GO evaluation of biological processes, interferon signaling was decreased in monocytes when comparing severe to moderate groups. Similarly, respiratory viral signaling pathways were also uniquely suppressed only within monocytes when comparing severe to moderate groups. Notably, PD-1/PD-L1 signaling, an immunologic checkpoint inhibitory pathway, was higher in monocytes within the severe group which could be contributing to the suppressed response of this cellular compartment.

Interferon signaling (both type I and II) was a prominent pathway that was repeatedly enriched in our comparison of the severe versus moderate groups. We used IPA to perform an upstream regulator analysis for each cell type (severe versus moderate) based on the cell type's J o u r n a l P r e -p r o o f 14 pattern of differential gene expression and also identified IRF7 as one of the most significant regulators consistently enriched in lymphocytes (Fig. 7B ). We constructed a mechanistic network with IRF7 as the master regulator and found that type I interferon signaling components were enriched as highly interactive nodes (Kramer et al., 2014) . Using this framework, we assessed which of the hierarchical components were activated or inhibited in our data and found that lymphocyte subsets had the expected activation whereas monocytes had inhibition of type I interferon pathways (Fig. 7B) , which is consistent with our prior analysis. We also compiled the genes identified by GO analysis across all immune cell populations to evaluate common genes that were enriched in response to interferon signaling (Supplemental Fig. 5A -C).

The lymphocyte subsets from patients with severe disease had similarly elevated type I IFN responses (, consistent with enhanced IRF7 expression. In contrast, the classical monocytes from patients in the severe group were no more responsive than those from the moderate group, with lower expression of IRF1 and IRF9, perhaps due to subversion of TLR and RIG-I signaling by SARS-CoV-2, as was previously reported for SARS-CoV-1 (Hu et al., 2017; Li et al., 2016; Siu et al., 2009) . Consistent with this analysis, GO pathway analysis revealed a reduction in the response to IFN-γ compared to healthy controls and a weaker type I IFN response in monocytes from severe patients, which contrasts to the stronger lymphocytic responses (Supplemental Fig. 5D -H).

Finally, eIF2 signaling, a known target of many respiratory viruses (Groskreutz et al., 2010; Liu et al., 2020; Rabouw et al., 2020) , was the most significantly downregulated pathway across all cells (except monocytes) when comparing severe to moderate groups, whereas mTOR signaling was depressed in the severe versus recovering groups (Fig. 7A) . We investigated the mTOR canonical pathway in severe versus recovering groups and noted that several nutrient-sensing and stress response processes were downregulated in severe COVID-19 patients relative to those with moderate disease (Fig. 7C ). To better define how the components of the eIF2 pathway were altered in immune cells, we performed a gene product J o u r n a l P r e -p r o o f 15 interaction analysis using IPA. This network was built by initially including all eIF2-associated members and limiting gene product relationships to those with experimentally validated direct interactions. We observed that many members of this network were differentially expressed in patients with severe versus moderate COVID-19 disease including eIF1 and eIF2, as well as a number of ribosomal genes such as RPS6 that were previously reported to be downregulated in influenza virus infection (Fig. 7D , Supplemental Table 9 ) (Zhai et al., 2015) . This overrepresentation was more pronounced when assessing the most highly connected network nodes-i.e., hubs-suggesting that key drivers of the eIF2 pathway are affected in severe SARS-CoV-2 infection.

J o u r n a l P r e -p r o o f Discussion ARDS is driven by a dysregulated inflammatory response that has been largely described as a "cytokine storm" associated with severely ill patients infected with SARS-CoV-2.

A unique feature of the lung injury that perpetuates ARDS is a non-resolving inflammation even after the inciting factor, in this case SARS-CoV-2 infection, has resolved (Matthay et al., 2012) .

A growing literature has provided a better understanding of how immune cell dysfunction contributes to the inflammatory response in COVID-19 patients (Giamarellos-Bourboulis et al., 2020) . Several groups have adopted scRNA-seq as an approach to functionally interrogate distinct immune compartments (Hadjadj et al., 2020; Lee et al., 2020; Wen et al., 2020; Wilk et al., 2020) . Our data are largely consistent with those findings, but our study further delineates the profound immune dysregulation in COVID-19 patients with severe illness compared to those with moderate symptoms and those recovering from ARDS. Moreover, our findings were consistent with prior scRNA-seq studies that compared the transcriptome of the PBMCs from healthy versus COVID-19 patients and identified an inflammatory signal that increased with disease severity (Hadjadj et al., 2020; Wilk et al., 2020) . Focusing our analysis to COVID-19 patients with varying severity allowed us to deeply interrogate the immune cell dysfunction and differentiate those that have moderate disease from patients that develop ARDS. Our analysis revealed that although most immune cellular compartments had an expected hyperinflammatory response in severe patients, several key pathways were dysfunctional in severely ill patients, which could be contributing to their inability to control the viral infection. Indeed, PBMCs from the severe group had a transcriptomic signal suggesting deficiencies in functions necessary to clear the virus: cytotoxic killing in NK and T cells, B cell activation, impaired antigen presentation by monocytes. Together, these findings indicate that distinct functional impairments in innate and adaptive immune responses during SARS-CoV-2 infection contribute to the disease severity.

One of the first immunologic features identified in COVID-19 patients was decreased but hyperactive lymphocytes (Song et al., 2020; Xu et al., 2020) . Our data suggest that both CD4 and CD8 T lymphocytes have a normal response to the viral pathogen with activation of antiviral pathways and a resultant hypermetabolic state. Notably, we found an increase in mitochondrial respiratory chain activity in the severe group, which could reflect a MAVS response to the SARS-CoV-2 infection (Moreno-Altamirano et al., 2019; Shi et al., 2014) . It has also been suggested that lymphocytopenia results from increased apoptosis, which is consistent with our findings (Vabret et al., 2020; Xiong et al., 2020) . Additionally, our analysis indicates that CD8 T lymphocytes have a deficiency in cell killing that could be contributing to the pathobiology of ARDS in COVID-19 patients. Similarly, NK cells had a transcriptomic signature that indicated defective effector killing of virally infected cells in severe patients. Clinical data on COVID-19 patients reported high respiratory viral load and impaired clearance in severe disease compared to moderate cases . Additionally, studies in COVID-19 patients have found that SARS-CoV-2 persisted longer in respiratory samples of severe patients in comparison to those with milder symptoms, and this delayed viral clearance coincides with more lung damage from the infection (Chang et al., 2020; Zheng et al., 2020) . Collectively, these results demonstrate a functional defect in both the innate and adaptive cytotoxic lymphocytic responses in COVID-19 patients with ARDS that could be contributing to the severity of disease.

Successful viral clearance relies on adaptive T cell and B cell immunity. Whereas

differentiate into antibody-producing plasma cells and memory B cells (Liao et al., 2017; Vos et al., 2000) . Delayed IgM has been reported in severely ill COVID-19 patients suggesting a defect in B cell function, though it is unclear if this is due to direct defects in B cells or in CD4 T helper cells (Shen et al., 2020) . Our findings suggest CD4 T lymphocytes have normal activity despite the decreased numbers described in COVID-19 patients. In contrast, pathways involved in B cell activation were downregulated in the severe group suggesting an inherent dysfunction in J o u r n a l P r e -p r o o f the B lymphocyte compartment that limits their activity. Moreover, SYK, which is essential for B cell activation, was identified as the most significant upstream regulator that was downregulated in B cells within the severe group (Cheng et al., 1995; Cornall et al., 2000) . Although recovery from SARS-CoV-2 infection is not fully dependent on B cell function and antibody production (Fallet et al., 2020) , these immune cells likely still have an important role in controlling the severity of disease, and a dysfunctional humoral response may result in higher viral titers and delayed viral clearance that could contribute to the development of ARDS during SARS-CoV-2 infection.

Much attention has been devoted to lymphocyte dysfunction in COVID-19, particularly to the importance of cytotoxic T cells in overcoming viral infection (De Biasi et al., 2020; Diao et al., 2020; Song et al., 2020) . Yet the most dramatic difference we found in the severe group was a marked decline in monocyte function. We identified excessive activation of ER stress in monocytes with a concomitant increase in apoptosis, which could be augmenting death of these immune cells in the severe group. Peripheral blood monocytes also had a deficiency in their response to interferon signaling. Type I interferon activity is important during an appropriate antiviral immune response (Acharya et al., 2020) , but a recent study demonstrated that severe COVID-19 patients have an apparent deficiency in type I interferon signaling (Hadjadj et al., 2020) . Our findings are congruous with this finding but further reveal that the deficient type I interferon response emanates from the monocytic compartment in contrast to lymphocytes, which had an appropriate response. Circulating monocytes from the severe group may be exhibiting immunoparalysis (Giamarellos-Bourboulis et al., 2020) , as our results imply that they were not responsive to interferon signaling. Sudden loss of monocytes and their MHC expression is an indicator of severe acute illness in other conditions characterized by "cytokine storm" such as sepsis and community acquired infections (Cajander et al., 2016; Lekkou et al., 2004) . We also found that monocytes were characterized by decreased expression of class I and II MHC genes in the severe group consistent with other descriptions (Giamarellos-J o u r n a l P r e -p r o o f 19 Bourboulis et al., Wilk et al., 2020) , which may be related to reduced responsiveness to both type I IFN and IFN-γ. A concomitant augmentation of PD-1/PD-L1 signaling was found in monocytes, which could lead to selective immunosuppression in this population. Additionally, we postulate that suppressed protein translation by an augmented unfolded protein response in monocytes may be further contributing to the immunoparalysis phenotype identified in the myeloid compartment. We also identified IRF7 as a master regulator that could be driving the aberrant type I interferon response in severe conditions, perhaps as a consequence of SARS-CoV-2 suppression of TLR/RIG-I signaling (Hu et al., 2017; Li et al., 2016; Siu et al., 2009 ).

Consequently, altered antigen presentation by monocytes can also result in the observed defect in T cell function in the severe group resulting in inhibition of the downstream adaptive immunity necessary for viral clearance and resolution of systemic inflammation (Jakubzick et al., 2017) .

Several cytokines have been found to be dysregulated in COVID-19 patients (Vabret et al., 2020) . Type I interferons are crucial for a successful antiviral immune response, and subverting the early type I interferon response contributes to pathogenesis in MERS-CoV, SARS-CoV-1, and SARS-CoV-2 infections (Hadjadj et al., 2020; Lee et al., 2020; Siu et al., 2009; Yang et al., 2015) . Clinical trials with type I interferon therapy are ongoing, however, this treatment may be harmful if patients are already upregulating interferon stimulated genes. In fact, our pathway analysis suggests adaptive immune cells have a normal interferon response, but monocytes have a selective dysregulation with a depressed interferon response in severe COVID-19 patients. Furthermore, our findings suggest that monocytes in severe patients have an inherent defect in their ability to respond to interferon signaling, and this dysfunction may not be ameliorated by simply treating patients at high risk for developing ARDS from SARS-CoV-2 infection with type I interferon (Acharya et al., 2020) .

PBMCs. However, immune cells do not express ACE2, the receptor required for viral entry, suggesting an inability for viral infection (Hamming et al., 2004; Hoffmann et al., 2020;  J o u r n a l P r e -p r o o f 20 Radzikowska et al., 2020; Zou et al., 2020) . Moreover, we did not find any evidence of ACE2 expression or any viral RNA in our scRNA-seq of PBMCs (unpublished). These observations make it less likely, but do not exclude the possibility that viral infection of immune cells is antagonizing inflammatory signaling pathways. An alternative explanation is that genetic, environmental, and age-related changes could confer a predisposition to a dysregulated response to pro-inflammatory signals. This concept has been previously demonstrated where certain individuals having attenuated while others have augmented inflammatory responses upon LPS stimulation of PBMCs (Wurfel et al., 2005) . Recently, a loss-of-function mutation in TLR7 was found to decrease the interferon response and was associated with the development of severe COVID-19 disease in small group of young men (van der Made et al., 2020). Aging, a risk for more severe COVID-19 illness, could also be contributing to immunoparalysis (Ebinger et al., 2020; Fulop et al., 2017; Grasselli et al., 2020) . Indeed, sirtuin signaling was uniformly depressed in all immune cell compartments of the severe group irrespective of comparison to moderate or recovering patients. Sirtuins are histone deacetylases that have diverse effects in antiviral defense and controlling longevity, inflammation, and cellular senescence (Budayeva et al., 2016; Imai and Guarente, 2014; Koyuncu et al., 2014) . In particular, sirtuin activity decreases with age, and immunosenescence could be driving some of the dysregulated immune response in severe patients (Fulop et al., 2017) . Obesity is another risk factor for development of severe COVID-19 disease (Ebinger et al., 2020) , and immunometabolic alterations could be contributing to the dysfunctional immune response in COVID-19 patients.

The immunomodulatory effects of obesity can alter both the innate and adaptive arms of the immune system and have profound effects in tissue inflammation (Hotamisligil, 2017) .

Autophagy has a prominent role in immunometabolism (Rathmell, 2012) , and our findings demonstrate disrupted mTOR signaling in multiple cellular compartments of severe patients particularly when compared to recovering patients suggesting another possible link to the dysregulated immunologic findings in COVID-19 patients.

J o u r n a l P r e -p r o o f 21 In summary, our study supports the concept that COVID-19, and especially severe cases that have progressed to ARDS, is characterized by multifaceted immune dysregulation that is not uniformly hyperinflammatory but more accurately described as a state of immune imbalance. Although immune cells have augmented inflammatory signatures in severe patients compared to the moderate and recovering groups, transcriptomic analysis suggests distinct patterns of immunoparalysis such as impaired cytotoxic cell killing, attenuated B cell activation, and dysregulated monocyte antigen presentation that could contribute to the severity of illness.

It is unclear if the divergent immunological responses in patients with a moderate versus severe disease course are specific to SARS-CoV-2 infection or generalizable to other infectious and non-infectious causes of ARDS, and future research using larger sample sizes is needed to further delineate the transcriptional landscape of immune cells in different ARDS populations.

However, our study suggests that therapies should consider a nuanced approach, particularly those involving targeted augmentation of pathways within specific immune compartments to limit disease severity as well as promote resolution of the unrelenting inflammation in COVID-19-associated ARDS. Kruskal-Wallis tests was used to test overall significance in module scores, P<2.2 x 10 -16 .

Wilcoxon test was used for pairwise comparisons, ****P<0.0001. Some of the nodes do not represent a single differentially expressed gene but potentially a family of genes (e.g, 40S Ribosome). D) Gene product interaction network analysis of the eIF2 pathway, which is downregulated in lymphocytes, but not monocytes, in the severe versus moderate group. A majority of the interactome's nodes were differentially expressed across cell types, particularly within the densely connected network hubs shown in the center (selectively labeled in the figure, and fully detailed in Supplemental Table 9 ). 

Further information and requests for reagents may be directed to, and will be fulfilled by the corresponding author Peter Chen (peter.chen@cshs.org).

This study did not generate new unique materials.

All the sequencing data along with their associated metadata have been deposited in the GEO database under accession code GSE154567.

This study was approved by Institutional Review Board at Cedars-Sinai Medical Center (CSMC; IRB# STUDY00000602). Informed consent was obtained from all enrolled patients according to CSMC BioBank's Phase 2 Protocol (IRB# PRO00043021).

Patients admitted to CSMC and diagnosed with COVID-19 by RT-PCR of nasopharyngeal swabs were stratified into moderate, severe, and recovery groups (n=6/group). One sample in the moderate group was lost during processing. The patient cohort included 9 females and 8 males between the ages of 35-85 (Refer to Supplemental Table 1 hospitalization. Instead of sample collection based on days of symptoms, which is subjective and liable to variability, we chose to collect samples within 5 days of admission from moderate and severe groups to maintain uniformity of timing for comparison between groups based on disease severity and reduce the potential for therapeutic interventions to confound interpretation of differences in immune cell gene expression between patients and groups. Furthermore, we collected samples from a recovery group comprised of patients 18 to 25 days after admission who were recovering from ARDS secondary to SARS-CoV-2 infection. Venous blood was collected into EDTA coated tubes and centrifuged to separate plasma and buffy coat. Plasma was collected and frozen at -80C, and the buffy coat was collected into cryo-preservation media and frozen at -80C. Our analyses focused on comparing differences between the moderate versus severe and severe versus recovery groups. Because the moderate and recovery groups had different acuity and severity, these two groups were not directly compared with each other.

Sample processing and single cell RNA-seq

The frozen buffy coats were thawed and washed with PBS containing 10% FBS. The cells were stained with DAPI (3µM) for 5 min to assess viability. Live cells were sorted using a BD FACS Aria III (BD Biosciences, San Jose, CA, USA) in the CSMC Flow Cytometry Core. Totalseq-A human hashing antibodies (Biolegend) were used to label FACS sorted cells. Pairs of hashed samples from the same patient group were mixed together at a 1:1 ratio before methanol fixation using the 10X Genomics methanol fixation protocol (Chen et al., 2018 (Stoeckius et al., 2018) .

Single cell analysis R package Seurat v3.1.5 was used for data analysis (Stuart et al., 2019) .

For quality control and filtering out low quality cells, only cells expressing more than 200 genes (defined as genes detected in at least 3 cells) and fewer than 20% mitochondrial genes were selected. To minimize doublet contamination for each dataset, we removed cells with a high number of genes detected using a fit model generated from suggested mulitplet rate over number of cells recovered as in the 10X Genomics user manual. Ambient RNA derived from lysed cells was removed using SoupX package (Matthew D. Young, 2018) . A total number of 69983 captured single cells (about 4000 cells per patient) passed quality control for further batch correction and unbiased clustering. We used default normalization and data scaling from Seurat package, which is a log normalization and linear model for data scaling. Batch correction package Harmony with Seurat 3 wrapper was used for data integration (Korsunsky et al., 2019) .

The batch correction was processed with PCA (Principal Component Analysis) using the 5000 most variable genes, and the first 20 independent components were used for downstream Differentially expressed genes between different clusters and groups were calculated using

Mode-based Analysis of Single-cell transcriptomics (MAST) (Finak et al., 2015) . Major immune cell types were assigned according their expression of known cell type specific gene signatures (Supplemental Fig. 1 and Supplemental 

To understand the biological processes that were enriched by the differentially expressed genes within each immune compartment, we sorted differentially expressed genes (FDR < 0.01) into those that were upregulated or downregulated between two groups (i.e., moderate versus severe and severe versus recovering) and did further analysis of gene lists separately. Using

Webgestalt (Version 2019) (Liao et al., 2019) , gene lists were entered to do an overrepresentation analysis using the Gene Ontology (GO) database to identify the biological processes that were affected by the differentially expressed genes between severity groups in each cell type. Upstream regulator analysis was performed by using differentially expressed genes (FDR < 0.01) for each immune cell type as input seeds. The direction of expression of these genes was compared to IPA's knowledge base using a statistical model (Kramer et al., 2014) to

identify key putative regulators and construct a mechanistic regulatory network. An overlap Pvalue was used to measure enrichment of network-regulated genes in the dataset and an activation z-score was calculated to identify likely regulating molecules based on statistically significant patterns of up-and downregulation as well as expected activation state (activated or inhibited) of each regulator.

Pathway module scores within each immune compartment were determined using the union of differentially expressed genes in all COVID-19 groups returned from GO overrepresentation analysis for biological processes of interest. Pathways were defined by the GO database. Genes present from the sorted differentially expressed genes that are attributed to a biological process or pathway of interest by the GO database were used to form the modules, and module genes were selected based on actual enriched GO processes. Pathway module scores were calculated using the AddModuleScore function of the Seurat package that J o u r n a l P r e -p r o o f 36 calculated the average expression of each gene signature list and subtracted by the aggregated expression of control feature sets. All analyzed features are binned based on averaged expression, and the control features are randomly selected from each bin (Tirosh et al., 2016) . Supplemental Table 9 : Canonical pathway list comparing severe and moderate of different cell types, and gene list and network for eIF2 pathway. Related to Figure 7 .

Yao et al. provide evidence that widespread, cell-specific dysregulation of immune responses in COVID-19 patients with acute respiratory distress syndrome may underlie disease severity. Defects include impaired antigen presentation pathways, suppressed monocyte response to early antiviral interferon signals, deficient lymphocyte expression of cytotoxicity genes, and reduced B cell activation.

• Defective immune responses distinguish severe COVID-19 from moderate disease • Monocyte antigen presentation pathway gene expression is lower in severe COVID-19

• Lymphocyte cytotoxicity pathways are reduced, and B cell activation is blunted • Interferon signaling is elevated in lymphocytes but diminished in monocytes J o u r n a l P r e -p r o o f A B

Signaling Module Score TCF3  ZBTB7A  VAV3  SUPT6H  CD22  PLCL2  DOCK10  PTPRC  INPP5D  PRKDC  SLC39A10  ITFG2  FCRL3  BCL2  STAT6  TBC1D10C  SYK  IKZF3  POU2F2  AKAP17A  DOCK11  PIK3R1  EP300  LFNG  ITGA4  SWAP70  BTK  FCRL1  ATM  MEF2C  KLF6 BANK1 PRKCB

Severe v. Recovering 

Natural Killer Cells: Development, Maturation, and Clinical Utilization

Dysregulation of type I interferon responses in COVID-19

Lymphopenic Community Acquired Pneumonia (L-CAP), an Immunological Phenotype Associated with Higher Risk of Mortality

Intricate Roles of Mammalian Sirtuins in Defense against Viral Pathogens

Quantitative Real-Time Polymerase Chain Reaction Measurement of HLA-DRA Gene Expression in Whole Blood Is Highly Reproducible and Shows Changes That Reflect Dynamic Shifts in Monocyte Surface HLA-DR Expression during the Course of Sepsis

Persistent Viral Presence Determines the Clinical Course of the Disease in COVID-19

PBMC fixation and processing for Chromium single-cell RNA sequencing

Syk tyrosine kinase required for mouse viability and B-cell development

Antiviral B cell and T cell immunity in the lungs

Role of Syk in B-cell development and antigen-receptor signaling

Origin and evolution of pathogenic coronaviruses

Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia

Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

Pre-existing traits associated with covid-19 illness severity

Acute Viral Respiratory Infection Rapidly Induces a CD8+ T Cell Exhaustion-like Phenotype

Mild course of Coronavirus disease

COVID-19: Immunology and treatment options

MAST: a flexible statistical framework for assessing transcriptional changes and characterizing heterogeneity in single-cell RNA sequencing data

Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes? Front Immunol 8

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in

Respiratory syncytial virus limits alpha subunit of eukaryotic translation initiation factor 2 (eIF2alpha) phosphorylation to maintain translation and viral replication

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Foundations of Immunometabolism and Implications for Metabolic Health and Disease

The Severe Acute Respiratory Syndrome Coronavirus Nucleocapsid Inhibits Type I Interferon Production by Interfering with TRIM25-Mediated RIG-I Ubiquitination

NAD+ and sirtuins in aging and disease

Monocyte differentiation and antigen-presenting functions

T cell exhaustion during persistent viral infections

Fast, sensitive and accurate integration of singlecell data with Harmony

Sirtuins are evolutionarily conserved viral restriction factors

Causal analysis approaches in Ingenuity Pathway Analysis

Immunophenotyping of COVID-19 and influenza highlights the role of

Cytokine production and monocyte HLA-DR expression as predictors of outcome for patients with community-acquired severe infections

Toll-like receptors in antiviral innate immunity

SARS Coronavirus Papain-Like Protease Inhibits the TLR7 Signaling Pathway through Removing Lys63-Linked Polyubiquitination of TRAF3 and TRAF6

Characterization of T-Dependent and T-Independent B Cell Responses to a Virus-like Particle

WebGestalt 2019: gene set analysis toolkit with revamped UIs and APIs

The role of host eIF2alpha in viral infection

The acute respiratory distress syndrome

SoupX removes ambient RNA contamination from droplet based single cell RNA sequencing data

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

The SYK tyrosine kinase: a crucial player in diverse biological functions

Virus Control of Cell Metabolism for Replication and Evasion of Host Immune Responses

T cell pathways involving CTLA4 contribute to a model of acute lung injury

Inhibition of the integrated stress response by viral proteins that block p-eIF2-eIF2B association

Distribution of ACE2, CD147, CD26 and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors

Metabolism and autophagy in the immune system: immunometabolism comes of age

Susceptibility to programmed cell death in Tlymphocytes from septic patients: a mechanism for lymphopenia

Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression

SARS-coronavirus open reading frame-9b suppresses innate immunity by targeting mitochondria and the MAVS/TRAF3/TRAF6 signalosome

Clinical characteristics and factors associated with long-term viral excretion in patients with SARS-CoV-2 infection: a single center 28-day study

Severe acute respiratory syndrome coronavirus M protein inhibits type I interferon production by impeding the formation of TRAF3.TANK.TBK1/IKKepsilon complex

Immunological and inflammatory profiles in mild and severe cases of COVID-19

Cell Hashing with barcoded antibodies enables multiplexing and doublet detection for single cell genomics

Comprehensive Integration of Single-Cell Data

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

Immunology of COVID-19: Current State of the Science

Presence of Genetic Variants Among Young Men With Severe COVID-19

B-cell activation by T-cellindependent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms

A single-cell atlas of the peripheral immune response in patients with severe COVID-19

Insights into the immunopathogenesis of acute respiratory distress syndrome

Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China

Cases From the Chinese Center for Disease Control and Prevention

Identification of high and low responders to lipopolysaccharide in normal subjects: an unbiased approach to identify modulators of innate immunity

Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19

Middle East respiratory syndrome coronavirus ORF4b protein inhibits type I interferon production through both cytoplasmic and nuclear targets

The pathogenesis and treatment of the `Cytokine Storm' in COVID-19

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

Host Transcriptional Response to Influenza and Other Acute Respiratory Viral Infections--A Prospective Cohort Study

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province

A Novel Coronavirus from Patients with Pneumonia in China

Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection

We thank the staff of the Biobank & Translational Research Core, the Flow Cytometry Core, and the Applied Genomics